-
- 175 Million Europeans Have Sleep Apnoea, Highlighting Scale of Global Health Crisis
- Roughly 175 million Europeans have obstructive sleep apnoea, according to a late-breaking abstract presented by ResMed today at the European Respiratory Society’s annual ERS Congress in Paris. Leading researc...
- 2018-09-21
-
- MEDTEX: Foresee the Next Wave of Healthcare Revolution
- Taiwan, with high quality medical service and world’s top IT industry, has becoming one of the leaders in global healthcare technology and provider. On November 29 - 30, MEDTEX will focus on 3 key trends: Int...
- 2018-09-18
-
- Clinical trial data for nintedanib in patients with advanced IPF published
- Results from the INSTAGE® trial have been presented at the 2018 European Respiratory Society (ERS) conference in Paris and published in the New England Journal of Medicine. The trial reports clinical data on a...
- 2018-09-17
-
- OptraSCAN® Receives CE Mark Approval for In-Vitro Diagnostics Use
- OptraSCAN®, the leading end-to-end digital pathology solution provider, today announced that their whole-slide scanners have received CE Mark approval for European Standards applicable to “In-Vitro Diagnosti...
- 2018-09-14
-
- New Study Investigates the Utility of Home Monitoring Using Masimo SET® Pulse Oximetry to Screen Children with Down Syndrome for Risk of Obstructive Sleep Apnea Prior to Diagnostic Multichannel Sleep Studies
- Masimo announced today the findings of a recently published study in which researchers investigated whether home pulse oximetry monitoring might be a useful initial screening method of determining which childre...
- 2018-08-14
-
- Graminex® LLC successfully challenges Serelys’ patents for use of pollen extracts in treating women's PMS and menopausal symptoms
- Graminex® LLC is pleased to announce the US Patent Office has rejected Serelys’ patents for use of its pollen extracts in treating women's PMS and menopausal symptoms. In parallel reexamination proceedings a...
- 2018-08-03
-
- Takeda Announces Phase 3 Trial of ALUNBRIG® (brigatinib) Met Primary Endpoint Demonstrating Superiority in Progression-Free Survival Versus Crizotinib in Patients with ALK+ Advanced NSCLC Who are ALK Inhibitor Naïve
- Takeda Pharmaceutical Company Limited today announced that the global, randomized, Phase 3 ALTA-1L (ALK in Lung Cancer Trial of AP26113 in 1st Line) trial met its primary endpoint at the first pre-specified int...
- 2018-07-26
-
- New Phase 3 Data Show Investigational Subcutaneous Formulation of Vedolizumab Meets Primary Endpoint in Achieving Clinical Remission at Week 52 in Patients with Moderately to Severely Active Ulcerative Colitis
- Takeda Pharmaceutical Company Limited today announced top-line results from the VISIBLE 1 clinical trial evaluating the efficacy and safety of an investigational subcutaneous (SC) formulation of vedolizumab for...
- 2018-07-20
-
- Phase 3 Trial of NINLARO® (ixazomib) as Maintenance Therapy Met Primary Endpoint Demonstrating Statistically Significant Improvement in Progression-Free Survival in Patients with Multiple Myeloma Post-Transplant
- Takeda Pharmaceutical Company Limited today announced that the randomized, Phase 3 TOURMALINE-MM3 study met its primary endpoint, demonstrating single-agent oral NINLARO® (ixazomib) as a maintenance therapy re...
- 2018-07-13
-
- New Analysis of Rekovelle® Data Further Supports Use of AMH to Personalise Fertility Treatment
- Ferring Pharmaceuticals announced today a new analysis* of data from the Phase 3 ESTHER-1 trial showing that natural variations in anti-Müllerian hormone (AMH) levels during and between a woman’s menstrual c...
- 2018-07-04
-
- CHMP issues positive opinion to expand Jardiance®, Synjardy® and Glyxambi® labels to include positive effects on cardiovascular and renal outcomes
- Boehringer Ingelheim and Eli Lilly and Company (NYSE:LLY) announced today that the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion to update t...
- 2018-07-03
-
- Boehringer Ingelheim and Lilly announce positive top-line Phase III data results for empagliflozin as adjunct to insulin in type 1 diabetes
- Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) today announced that both randomised controlled trials in the EASE phase III programme, investigating the use of empagliflozin in combination with insu...
- 2018-06-27
-
- Takeda Announces Term Loan Credit Agreement and Amendment to Bridge Credit Agreement in Connection with Proposed Shire Acquisition
- Takeda Pharmaceutical Company Limited (TSE: 4502) (“Takeda”) announces that it has today entered into a term loan credit agreement for an aggregate principal amount of up to 7.5 billion USD with leading glo...
- 2018-06-11
-
- Sonion and Valencell Partner to Make Biometrics Universal in Hearables and Hearing Health Markets
- Sonion, the global leader in micro acoustic and micro mechanical technologies and solutions for hearing instruments and specialty earphones, and Valencell, the leading innovator in wearable biometric sensor tec...
- 2018-06-07
-
- New Study Investigates the Utility of Continuous Noninvasive Hemoglobin Measurement With Masimo SpHb® for Reflecting Real-time Iatrogenic Hemodilution During Incremental Fluid Administration
- [트리니티메디컬뉴스=신민철기자] Masimo (NASDAQ:MASI) announced today the findings of an abstract presented at Euroanaesthesia 2018 in which researchers compared Masimo noninvasive and continuous h...
- 2018-06-06
-
- Ferring Signs Global Agreement to Commercialise Novel Gene Therapy for Bladder Cancer Patients
- Ferring Pharmaceuticals today announced the signing of an agreement giving the company the option to secure global commercialisation rights to nadofaragene firadenovec/Syn3 (rAd-IFN/Syn3), a novel gene therapy ...
- 2018-05-04
-
- Boston Healthcare Adds Seasoned Market Access Leader to Global Life Science Consulting Team
- Boston Healthcare Associates Inc. (Boston Healthcare), a global life sciences consulting firm, today announced that Mark Girardi has joined the firm as Vice President to further develop a growing national and i...
- 2018-05-03
-
- Boehringer Ingelheim R&D Pushes to Transcend Disease Boundaries
- [트리니티메디컬뉴스=신민철기자] Family-owned pharmaceutical company Boehringer Ingelheim today presented its latest pipeline updates at a Research & Development press conference entitled ‘Transc...
- 2018-04-26
-
- New Analyses from Pivotal Phase III Trials of Oral Ozanimod in Relapsing Multiple Sclerosis To Be Presented at the 2018 American Academy of Neurology Annual Meeting
- [트리니티메디컬뉴스=신민철기자] Celgene Corporation (NASDAQ:CELG) today announced additional phase III data analyses evaluating the efficacy and safety of ozanimod, a novel, oral, selective sphing...
- 2018-04-25
-
- New Study Investigates the Performance of Masimo SpHb® During Acute Bleeding and After Fluid Resuscitation
- Masimo (NASDAQ: MASI) announced today the findings of a recently published study in which researchers at Cairo University in Egypt evaluated the accuracy and trending of Masimo noninvasive and continuous hemogl...
- 2018-03-13
- 기획특집 2 - 미세먼지더보기
-
-
- 도로포장 신기술로 미세먼지 잡는다
- 서울시가 미세먼지의 원인이 되는 질소산화물 정화기능이 있는 ‘광촉매’를 활용한 도로포장 신기술을 전국 최초로 도입한다고 28일 밝혔다. 이 기술은 도로 포장면에 광촉매를 뿌려 자동차 배기가스의 주성분인 질소산화물을 분해하는 방식으로, 도로 위 미세먼지를 줄일 수 있을 것으로 기대된다. 이와...
-
- 미세먼지 영향, 알레르기 비염 환자도 급증했다
- 보건복지부(박능후 장관)가 '통계로 보는 사회보장 2017'을 발간한다고 6일 밝혔다. 보건복지부는 국민의 삶의 질과 관련된 각 분야를 조사해 가족, 환경, 교육, 근로, 건강 등 11개 분야와 262개 지표로 구성했다. 이번에 공개한 통계 중에서 국민 기초생활보장제도 수급률이 눈에 띄게 상승했다. 2009년부터 5...
-
- 전국 미세먼지 나쁨 예보, 노약자·임산부·기저질환자 특히 주의
- [트리니티메디컬뉴스=신민철기자] 질병관리본부(본부장 정은경)는 23일 봄철 미세먼지 농도 나쁨이 예보된 가운데 어린이, 어르신, 임산부, 기저질환자(호흡기질환, 심뇌혈관질환, 천식)는 건강보호에 더 각별한 주의를 기울여 줄 것을 당부했다. 미세먼지는 피부와 눈, 코 또는 인후 점막에 직접 접촉해 물리적 자극을 유발하고, 크기가 작아...
-
환경부, 미세먼지 환경 기준 미국 일본 수준으로 강화
-
서울시, ‘미세먼지 측정소’ 20m 이내로 이전
